Abstract: A shaft seal device according to at least one embodiment of the present disclosure includes: a plurality of thin plates arranged in a circumferential direction of a rotational shaft and each having a width in an axial direction of the rotational shaft and a seal ring including a seal mounting groove for mounting the plurality of thin plates. An inner wall of the seal mounting groove on one side in the axial direction has a groove formed along the circumferential direction, in an inner region in a radial direction of the rotational shaft.

Abstract: A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.

Abstract: Methods for prevention and reversal of inflammation.

Abstract: Methods for the reversal of hemorrhagic shock or hemorrhagic trauma.

Abstract: Method for transfusion medicine to reduce adverse events in transfusion patient populations based on underlying patient physiology.

Abstract: Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.

Abstract: Methods and compositions for improved clinical outcomes for trauma patients receiving whole blood transfusion. Methods and compositions for improved clinical outcomes for blood transfusions for cancer patients are also provided.

Abstract: Relates to a method for pathogen reduction of a blood product comprising: i) removing oxygen from a blood product; ii) reducing blood pathogens from said blood product t: adding amustaline (S-303) to a final concentration of 0.2 millimolar (mM); and glutathione (GSH) to a concentration of 20 mM; iii) reducing S-303 to a concentration of less than 1 nmol/L comprising incubating said oxygen reduced blood product under oxygen reduced conditions for up to 6 hours; and further relates to a pathogen reduced, oxygen reduced blood product having an oxygen saturation (sO2) of less than 25%, a pCO2 of 90 mmHg or less at 37° C., and having a amustaline (S-303) concentration of less than 1 nmol/L.

Abstract: A system and methodology for the preservation of red blood cells is described in which red blood cells are oxygen or oxygen and carbon dioxide depleted, treated and are stored in an anaerobic environment to optimize preparation for transfusion. More particularly, a system and method for extended storage of red blood cells from collection to transfusion that optimizes red blood cells prior to transfusion is described.

Abstract: This application provides methods, compositions, and kits for use blood group determination and the preparation of improved red blood cell containing reagents for use in blood typing of blood prior to its use in transfusion medicine.

Abstract: A system and methodology for the preservation of red blood cells is described in which red blood cells are oxygen or oxygen and carbon dioxide depleted, treated and are stored in an anaerobic environment to optimize preparation for transfusion. More particularly, a system and method for extended storage of red blood cells from collection to transfusion that optimizes red blood cells prior to transfusion is described.

Abstract: Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.

Abstract: A blood storage system comprising: a collection vessel for red blood cells; an oxygen or oxygen and carbon dioxide depletion device; a storage vessel for red blood cells; tubing connecting the collection vessel to the oxygen or oxygen and carbon dioxide depletion device and the oxygen or oxygen and carbon dioxide depletion device to the storage vessel; and a gamma or X-ray irradiating device is used to irradiate red blood cells stored in the vessel, storing red blood cells under anaerobic conditions.

Abstract: A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.

Abstract: This application provides methods, compositions, and kits for use blood group determination and the preparation of improved red blood cell containing reagents for use in blood typing of blood prior to its use in transfusion medicine.

Abstract: Methods for prevention and reversal of inflammation.

Abstract: A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.

Abstract: Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.

Abstract: Methods and compositions for improved clinical outcomes for trauma patients receiving whole blood transfusion. Methods and compositions for improved clinical outcomes for blood transfusions for cancer patients are also provided.

Abstract: Method for transfusion medicine to reduce adverse events in transfusion patient populations based on underlying patient physiology. Methods for reducing the risk of an inflammatory response in a sickle cell patient in need of a blood transfusion.